Skip to main content


Editor's pick

Anticoagulants could stave off increased risk of dementia associated with AF


Study findings show an increased risk of dementia in older people with atrial fibrillation and support the use of anticoagulants to reduce the likelihood.

ECTRIMS 2018: Ongoing relapse activity is a suitable treatment target in secondary-progressive multiple sclerosis

Nathaniel Lizak presents study findings showing that ongoing relapse in patients with multiple sclerosis is not a contraindication to disease-modifying treatment (2:19).

ECTRIMS 2018: Better outcomes in relapsing MS patients switching to natalizumb versus fingolimod after first-line treatment

Tim Spelman discusses his team’s findings of a significant reduction in relapse rates and greater disability improvement in multiple sclerosis patients who relapse on first-line treatment and switch to natalizumab versus fingolimod (2:55).

ECTRIMS 2018: Focal cortical damage identifies MS patients at increased risk of frequent early relapses

Antonio Scalfari gives an overview of findings showing that early focal cortical lesions at multiple sclerosis onset is associated with earlier relapse and an increased risk of converting to secondary progressive multiple sclerosis (4:14).  

ECTRIMS 2018: Focal inflammatory brain disease associated with increased risk for cognitive disability

Wallace Brownlee talks about his group’s findings that conventional MRI measures of inflammatory disease could help identify patients with early multiple sclerosis who are at high risk of developing cognitive disability (3:05).

ECTRIMS 2018: Real-world data support early treatment initiation in relapsing-remitting MS patients

Pietro Iaffaldano shares his real-world findings from the Big Multiple Sclerosis Data Network showing an optimal time to treatment initiation of 6 months in patients with relapsing-remitting multiple sclerosis (1:51).

ECTRIMS 2018: McDonald 2017 criteria allows for earlier MS diagnosis than McDonald 2010 in patients with clinically isolated syndrome

Wallace Brownlee presents his study showing that the revised McDonald 2017 criteria are more sensitive than the McDonald 2010 criteria, albeit with a modest reduction in specificity, for diagnosing multiple sclerosis in patients with typical clinically isolated syndrome characteristics (3:49).

ECTRIMS 2018: Sensitivity for predicting a second MS episode increased with McDonald 2017 criteria

Roos M van der Vuurst de Vries discusses her McDonald 2017 criteria findings, which provide further support of improved sensitivity for diagnosing clinically definite multiple sclerosis in patients with clinically isolated syndrome (5:05).

ECTRIMS 2018: : ORATORIO extension-phase trial findings show sustained reduction in MS disability progression with ocrelizumab

Jerry Wolinksy summarises his findings from the open-label extension period of the phase III ORATORIO trial looking at sustained disability progression with ocrelizumab in patients with primary progressive multiple sclerosis (8:20).

ECTRIMS 2018: Novel 3-in-1 MS-SMART trial fails on efficacy end-points but paves the way for multi-arm strategies

18-10-2018 | Neurology | News | Article

Positive initial results for IGF-1 pathway as treatment target in spinal and bulbar muscular atrophy

The insulin-like growth factor-1 pathway may be a suitable treatment target for patients with spinal and bulbar muscular atrophy, suggest preliminary findings.


Lancet Neurol 2018; doi:10.1016/S1474-4422(18)30320-X

Lancet Neurol 2018; doi:10.1016/S1474-4422(18)30359-4

04-10-2018 | Neurology | News | Article

Global burden of Parkinson’s disease is on the rise

The global burden of Parkinson’s disease has more than doubled over the past 26 years, show findings from the Global Burden of Disease Study 2016.


Lancet Neurol 2018; doi:10.1016/S1474-4422(18)30295-3

Lancet Neurol 2018; doi:10.1016/S1474-4422(18)30355-7

27-09-2018 | Neurology | News | Article

Reclassification of juvenile Huntington’s disease may be required

A retrospective analysis of a cohort of children and adolescents with Huntington’s disease points to the presence of two juvenile forms that have markedly different clinical features and prognosis.


Lancet Neurol 2018; doi:10.1016/S1474-4422(18)30294-1

20-09-2018 | Alzheimer's disease | News | Article

Flortaucipir PET discriminates AD from other neurodegenerative disorders

The positron emission tomography tracer [18F]flortaucipir could be a useful test for distinguishing Alzheimer’s disease from other neurodegenerative disorders, say researchers.


JAMA 2018; 320: 1151–1162

13-09-2018 | Multiple sclerosis | News | Article

Fingolimod shows relapse benefits versus interferon beta-1a in paediatric multiple sclerosis

Adolescents with multiple sclerosis may experience fewer relapses if they take fingolimod versus interferon beta-1a, suggest findings from the phase III PARADIGMS trial.


New Engl J Med 2018; 379: 1017–1027

New Engl J Med 2018; 379: 1085–1086

06-09-2018 | Alzheimer's disease | News | Article

Biomarkers identified for diagnosing AD in patients with Down syndrome

Plasma neurofilament light protein concentrations and cerebrospinal fluid biomarkers are effective for diagnosing Alzheimer’s disease in patients with Down syndrome, say researchers.


Lancet Neurol 2018; doi:10.1016/S1474-4422(18)30285-0
Lancet Neurol 2018; doi:10.1016/S1474-4422(18)30293-X

Twitter Icon Follow medwireNews

Click here
image credits